Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
14,731
archived clinical trials in
Psychiatric

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
1212
mi
from 91732
Austin, TX
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
A Randomized, Double-Blind, Placebo-Controlled, Parellel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
1212
mi
from 91732
Austin, TX
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
2135
mi
from 91732
Tampa, FL
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
Updated: 1/1/1970
Univeristy of South Florida
2135
mi
from 91732
Tampa, FL
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
1524
mi
from 91732
Rochester, MN
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
1524
mi
from 91732
Rochester, MN
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
2438
mi
from 91732
Bronx, NY
Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD)
Wait-list Feasibility Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric OCD
Status: Archived
Updated: 1/1/1970
Fordham University
2438
mi
from 91732
Bronx, NY
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Status: Archived
2436
mi
from 91732
Brooklyn, NY
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
2436
mi
from 91732
Brooklyn, NY
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single-center Study, to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 Following Single Ascending Oral Dose Administration in Healthy Subjects
Status: Archived
1339
mi
from 91732
Kansas City, KA
Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451
A Phase I, Randomized, Double- Blind, Placebo- Controlled, Single-center Study, to Assess the Safety, Tolerability and Pharmacokinetics of AZD4451 Following Single Ascending Oral Dose Administration in Healthy Subjects
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1339
mi
from 91732
Kansas City, KA
Pilot Study of a Text Message Platform to Reduce Risky Drinking in Young Adults
Pilot Study of a Computer-driven Platform That Uses Text Messages to Collect Drinking Information and Deliver Personalized Motivational Messages to At-risk Young Adults
Status: Archived
2121
mi
from 91732
Pittsburgh, PA
Pilot Study of a Text Message Platform to Reduce Risky Drinking in Young Adults
Pilot Study of a Computer-driven Platform That Uses Text Messages to Collect Drinking Information and Deliver Personalized Motivational Messages to At-risk Young Adults
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
2121
mi
from 91732
Pittsburgh, PA
Medications Development for the Treatment of Cannabis Related Disorders
Medications Development for the Treatment of Cannabis Related Disorders
Status: Archived
2208
mi
from 91732
Charlottesville, VA
Medications Development for the Treatment of Cannabis Related Disorders
Medications Development for the Treatment of Cannabis Related Disorders
Status: Archived
Updated: 1/1/1970
University of Virginia Health Systems
2208
mi
from 91732
Charlottesville, VA
Medications Development for the Treatment of Cannabis Related Disorders
Medications Development for the Treatment of Cannabis Related Disorders
Status: Archived
2205
mi
from 91732
Charlottesville, VA
Medications Development for the Treatment of Cannabis Related Disorders
Medications Development for the Treatment of Cannabis Related Disorders
Status: Archived
Updated: 1/1/1970
University of Virginia
2205
mi
from 91732
Charlottesville, VA
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
1919
mi
from 91732
Atlanta, GA
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1919
mi
from 91732
Atlanta, GA
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
1354
mi
from 91732
Houston, TX
A Study to Evaluate the Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (Study P06522)
A Sequential Groups, Open Label, Rising Multiple Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1354
mi
from 91732
Houston, TX
Ketamine for Low Mood States in the ER
Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients
Status: Archived
2486
mi
from 91732
New Haven, CT
Ketamine for Low Mood States in the ER
Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
2486
mi
from 91732
New Haven, CT
Oxytocin Treatment of Alcohol Withdrawal
Oxytocin Treatment of Alcohol Withdrawal
Status: Archived
2189
mi
from 91732
Chapel Hill, NC
Oxytocin Treatment of Alcohol Withdrawal
Oxytocin Treatment of Alcohol Withdrawal
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
2189
mi
from 91732
Chapel Hill, NC
Oxytocin Treatment of Alcohol Withdrawal
Oxytocin Treatment of Alcohol Withdrawal
Status: Archived
2218
mi
from 91732
Raleigh, NC
Oxytocin Treatment of Alcohol Withdrawal
Oxytocin Treatment of Alcohol Withdrawal
Status: Archived
Updated: 1/1/1970
Central Regional Hospital
2218
mi
from 91732
Raleigh, NC
Studying Amphetamine Withdrawal in Humans
Amphetamine Withdrawal Paradigm in Humans
Status: Archived
1461
mi
from 91732
Little Rock, AR
Studying Amphetamine Withdrawal in Humans
Amphetamine Withdrawal Paradigm in Humans
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
1461
mi
from 91732
Little Rock, AR
Follow Up of Gestational Carriers and Intended Parents
Follow Up of Gestational Carriers and Intended Parents
Status: Archived
2407
mi
from 91732
Morristown, NJ
Follow Up of Gestational Carriers and Intended Parents
Follow Up of Gestational Carriers and Intended Parents
Status: Archived
Updated: 1/1/1970
Reproductive Medicine Associates of New Jersey
2407
mi
from 91732
Morristown, NJ
Efficacy of a Brief Nightmare Treatment for Veterans
Efficacy of a Brief Nightmare Treatment for Veterans
Status: Archived
1252
mi
from 91732
Tulsa, OK
Efficacy of a Brief Nightmare Treatment for Veterans
Efficacy of a Brief Nightmare Treatment for Veterans
Status: Archived
Updated: 1/1/1970
The University of Tulsa
1252
mi
from 91732
Tulsa, OK
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
2205
mi
from 91732
Durham, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International; Substance Abuse Treatment Evaluations and Interventions (SATEI) Community-Based Field Site - Durham
2205
mi
from 91732
Durham, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
2218
mi
from 91732
Raleigh, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International - Wake County Field Site
2218
mi
from 91732
Raleigh, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
2203
mi
from 91732
Research Triangle Park, NC
Young Women's CoOp Study
Adapting the Women's CoOp for At-Risk Teens
Status: Archived
Updated: 1/1/1970
RTI International - Headquarters
2203
mi
from 91732
Research Triangle Park, NC
Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy
Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy
Status: Archived
1725
mi
from 91732
Milwaukee, WI
Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy
Guitars for Vets: Evaluating Psychological Outcome of a Novel Music Therapy
Status: Archived
Updated: 1/1/1970
Zablocki VA Medical Center, Milwaukee
1725
mi
from 91732
Milwaukee, WI
A Study of Brain Receptor Occupancy in Healthy Subjects
Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects
Status: Archived
2497
mi
from 91732
Hartford, CT
A Study of Brain Receptor Occupancy in Healthy Subjects
Assessment of Brain Kappa Opioid Receptor Occupancy After Single Oral Doses of LY2456302 as Measured by PET With Radioligand LY2879788 in Healthy Subjects
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2497
mi
from 91732
Hartford, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1785
mi
from 91732
Birmingham, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #215
1785
mi
from 91732
Birmingham, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1787
mi
from 91732
Hoover, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 095
1787
mi
from 91732
Hoover, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1785
mi
from 91732
Huntsville, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #014
1785
mi
from 91732
Huntsville, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1749
mi
from 91732
Mobile, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #146
1749
mi
from 91732
Mobile, AL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
356
mi
from 91732
Chandler, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #171
356
mi
from 91732
Chandler, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
336
mi
from 91732
Glendale, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 145
336
mi
from 91732
Glendale, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
335
mi
from 91732
Glendale, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 027
335
mi
from 91732
Glendale, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
341
mi
from 91732
Phoenix, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 121
341
mi
from 91732
Phoenix, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
435
mi
from 91732
Tucson, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 137
435
mi
from 91732
Tucson, AZ
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1419
mi
from 91732
Hot Springs, AR
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 052
1419
mi
from 91732
Hot Springs, AR
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1452
mi
from 91732
Little Rock, AR
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 155
1452
mi
from 91732
Little Rock, AR
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
16
mi
from 91732
Buena Park, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #182
16
mi
from 91732
Buena Park, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
365
mi
from 91732
Sacramento, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 162
365
mi
from 91732
Sacramento, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
103
mi
from 91732
San Diego, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 008
103
mi
from 91732
San Diego, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
347
mi
from 91732
Walnut Creek, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 159
347
mi
from 91732
Walnut Creek, CA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
818
mi
from 91732
Denver, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 007
818
mi
from 91732
Denver, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
827
mi
from 91732
Denver, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #216
827
mi
from 91732
Denver, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
808
mi
from 91732
Lakewood, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 026
808
mi
from 91732
Lakewood, CO
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2492
mi
from 91732
New Britain, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
The Hospital of Central Connecticut at New Britain General
2492
mi
from 91732
New Britain, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2528
mi
from 91732
New London, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
Coastal Connecticut Research, LLC
2528
mi
from 91732
New London, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2456
mi
from 91732
Ridgefield, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 036
2456
mi
from 91732
Ridgefield, CT
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2135
mi
from 91732
Jacksonville, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 143
2135
mi
from 91732
Jacksonville, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2315
mi
from 91732
Miami, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 024
2315
mi
from 91732
Miami, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2185
mi
from 91732
Orlando, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #111
2185
mi
from 91732
Orlando, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2124
mi
from 91732
Pinellas Park, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #219
2124
mi
from 91732
Pinellas Park, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
2124
mi
from 91732
St. Petersburg, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 041
2124
mi
from 91732
St. Petersburg, FL
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1918
mi
from 91732
Atlanta, GA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site 115
1918
mi
from 91732
Atlanta, GA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
1915
mi
from 91732
Roswell, GA
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder
A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women
Status: Archived
Updated: 1/1/1970
BioSante Site #141
1915
mi
from 91732
Roswell, GA